IVVD实时信号 | 通过Getagraph.com最大化利润

购买 107636 min ago

@ $4.03

发出时间: 15 Feb 2024 @ 04:29

回报率: -46.15%

上一信号: Feb 14 - 03:11

上一信号: 出售

回报率: 1.26 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:24):

Stats
今日成交量	32 975.00
平均成交量	878 956
市值	258.71M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-0.510 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.200
ATR14	$0.0110 (0.51%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Green Julie	Buy	240 000	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	110 700	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	97 500	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	160 000	Stock Option (Right to Buy)
2024-01-19	Adimab, Llc	Sell	5 000 000	Common Stock

INSIDER POWER
7.60
Last 36 transactions
Buy: 9 419 589 \| Sell: 5 442 000

音量相关性

長: -0.25 (neutral)

短: -0.04 (neutral)

Signal:(56.452) Neutral

Invivyd, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Invivyd, Inc. 相关性 - 货币/商品

0.26
( neutral )

-0.03
( neutral )

0.00
( neutral )

-0.05
( neutral )

0.00
( neutral )

0.25
( neutral )

Invivyd, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-2.03M (0.00 %)
EPS:	$-1.810

FY	2023
营收:	$0
毛利润:	$-2.03M (0.00 %)
EPS:	$-1.810

FY	2022
营收:	$0
毛利润:	$-462 000 (0.00 %)
EPS:	$-2.17

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-5.32

Financial Reports:

No articles found.

Invivyd, Inc.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.